Page 45 - 74_03

VOL. 74 (3), 409-429, 2008 INFLUENCIA DE LA SIALILACIÓN Y DE LA...

(17) STOAN, I. et al. (2007): New alternatives for erythropoietin therapy in chronic
renal failure. Central Europ. J. Medicine 2: 361-378.

(18) STIEGLER, G.; KRESSE, G. B. and BUCKEL, P. (1997): Biotecnología de fármacos.
Inv. Ciencia. 254: 55-57.

(19) MACDOUGALL, I. C. (2000): Novel Erythropoiesis Stimulating Protein. Seminars
in Nephrology. 20: 315-381.

(20) MELNIKOU, F. (2006): Anaemia therapics. Nature Reviews. 5: 627.
(21) TAKEUCH, M. and KOBATA, A. (1991): Structures and functional roles of the

sugar chains of human erythropoietins. Glycobiology. 1: 337-346.
(22) EGRIE, J. C. et al. (1993): The role of the carbohydrate on the biological

activity of erithropoietin. Glyconjugate J. 10: 263.
(23) ERBAYRAKTAR, S. et al. (2003): Asialoerythropoietin is a nonerythropoietic cyto-

kine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. 100:
644-6746.
(24) BYRNE, B.; DONOHE, G. C. and O’KENNEDY, R. (2007): Sialic acids: carbohydrate
moieties that influence the biological and physical properties of biopharma-
ceutical proteins and living cells. Drug Discovery Today. 12: 319-326.
(25) GRAHAM, M. L. (2003): Pegaspargase: a review of clinical studies. Adv. Drug
Deliv. Rev. 55: 1293-1302.
(26) LEVY, Y. et al. (1988): Adenosine deaminase deficiency with late onset of
recurrent infections: response to treatment with polyethylene glycol-modified
adenosine deaminase. J. Pediatr. 113: 312-221.
(27) HARRIS, J. M. and CHESS, R. B. (2003): Effect of pegylation on phamarceuti-
cals. Nat. Rev. Drug Discov. 2: 214-221.
(28) MACDOUGALL, I. C. et al. (2006): Pharmacokinetics and Pharmacodynamics of
Intravenons and Subcutaneous Continuos Erythropoietin Receptor Activa-
tor (C.E.R.A.) in Patients with Chronic Kidney Disease. Clin. J. Am. Soc.
Nephrol., Sept 13 (doi: 10.2215).

429